ClinicalTrials.gg
RecruitingNCT05141474NEXTGENTIL-ACTUpdated Nov 20, 2026

Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors

An Early Phase 1 interventional study of NEXTGEN-TIL and Non-myeloablative Lymphodepletion (NMA-LD) Regimen in Epithelial Tumors, Malignant and Malignant Solid Tumor, sponsored by Vall d'Hebron Institute of Oncology. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Vall d'Hebron Institute of Oncology · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years later.
Updated Nov 20, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Carcinoma with a site in Spain — 13 open to participants now, 24 under way, 12 of them phase 3. Carcinoma · Spain.

Planned enrollment
81st of 82
10 · median 217
Started
2021
with 6 others
Phase 1
14 of 83
2 open now
Primary completion
2027-01
later than 8 of 23 live
Registered
71st of 83
by date

Among the 83 studies in Carcinoma with a site in Spain, this one is the 81st largest by planned enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2021, is one of 14 in phase 1, reaches primary completion later than 8 of the 23 other live ones, and was the 71st registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

13 of the 83 studies in Carcinoma with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Carcinoma with a site in Spain, or all of them as a file.
02

Study summary

Background:

The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead to remarkable antitumor responses supports that lymphocytes play a critical role in cancer immunity.

Adoptive cell therapy using tumor-infiltrating lymphocytes product (TIL-ACT) is a well-established combination therapy currently under study in several world reference centers, using an autologous cell product without genetic modifications. This cell product consists of tumor-infiltrating lymphocytes (TIL), which are collected from the patient and expanded in the lab under specific conditions to enhance its antitumoral efficacy before reinfusion in the same patient. However, this cell product alone does not achieve adequate efficacy, and a combination of both previous non-myeloablative lymphodepleting (NMA-LD) chemotherapy and subsequent cytokine therapy (specifically IL-2) is needed to support the expansion of the infused cells.

The investigators hypothesize that TILs enriched for neoantigen recognition are superior to unselected TILs at mediating tumor regression in patients with epithelial tumors and even other solid tumors where immune checkpoint blockade (ICB) is approved and used as part of standard therapy. The investigators propose to manufacture a T-cell product composed of TILs that are selected based on their ability to recognize patient-specific neoantigens and to use these to treat patients with metastatic, refractory, epithelial cancers, as well as ICB-resistant solid tumors. Furthermore, it also proposed to study the tumor and T cells at baseline and after treatment to investigate whether specific phenotypic and functional traits may be associated with clinical outcome.

Primary objective:

To evaluate the safety and the tolerability of ex vivo next generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) in patients with metastatic or unresectable epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors.

Secondary objectives:

  • To determine the success in producing active specific TILs from our target patients.
  • To evaluate the initial clinical activity of the NEXTGEN-TIL products in our target patients.
Read the detailed description

Methods:

This study is a first-in-human, open-label, non-controlled, single-centre, phase I trial to assess the safety and tolerability of NEXTGEN-TIL-ACT. Given the exploratory nature of the study, there is no formal hypothesis testing and no formal sample size calculation was carried out.

A sample size of 10 patients has been selected to provide information about the frequency of treatment-limiting toxicity (TLT).

Study treatment:

The main study therapy is the Tumor-infiltrating Lymphocyte (NEXTGEN-TIL) product, which is preceded by a preparative non-myeloablative lymphodepleting (NMA-DL) regimen and followed by IL-2 infusion.

NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor.

03

Conditions studied

  • Epithelial Tumors, Malignant
  • Malignant Solid Tumor

Browse trials for

Keywords

  • Immune checkpoint blockade resistant tumors
  • Tumor-infiltrating Lymphocyte
  • Adoptive Cell Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria in the pretreatment phase:

  1. Patients must have or cytologically proven or unresectable solid tumors. The disease must have progressed to at least one standard therapy (including at least one prior line with ICB for the group of patients with tumors where ICB is approved), or the patient is unable/unwilling to receive standard therapy or no standard therapy exists for a particular disease.
  2. Patients must have at least one adequate lesion (primary tumor or metastasis) for resection or for TIL generation with minimal morbidity (preferentially using imaging-guided minimally invasive procedures).

    Note: If this lesion was previously irradiated, the lesion must have demonstrated progression prior to resection/biopsy.

  3. Patient must be at least 18 years old at the tissue procurement visit.
  4. Patient must understand and voluntarily sign an document before any study-related assessments/procedures being conducted.
  5. Patient must be able and willing to comply to the study visit schedule and protocol requirements.
  6. Patients must have a clinical performance of 0 or 1.
  7. Patients are considered medically fit enough by investigator to undergo all study procedures and interventions.
  8. Patients with documented (LVEF) of ≥45%.
  9. Patients with documented forced expiratory volume at one second (), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) ≥50% tested by a pulmonary function test.
  10. Patients must be seronegative for antibody (patients who are HIV seropositive may be less responsive and more susceptible to toxicities related to this experimental treatment since they may have a decreased immune competence).
  11. Patients must be seronegative for active (defined as having a negative hepatitis B surface antigen [HBsAg] test), and seronegative for (HCV) antibody. Patients with a history of hepatitis B virus (HBV) infection and having a negative HBsAg test and a positive antibody to hepatitis B surface antigen (HBsAg) are eligible. Patients with the hepatitis C antibody test positive are eligible only if tested for the presence of antigen by RT-PCR and be HCV RNA negative.
  12. ≥6 months.
  13. Patients who are of (postmenarcheal who has not reached a state and has not undergone surgical sterilization) or have partners of childbearing potential must agree to use a highly effective method of during the study and for at least 6 months after the last dose of IL-2.

Inclusion Criteria in the treatment phase:

  1. The disease must have progressed to the last standard therapy, including at least one prior line with ICB for the group of patients with tumors where ICB is approved, and no subsequent approved therapy is available, or the patients are unable/unwilling to receive standard therapy, or no standard therapy exists for a particular disease.
  2. Patients must have a remaining as defined by v. 1.1 criteria following tumor resection/biopsy for NEXTGEN-TIL manufacturing.

    Note: Lesions previously irradiated should not be selected as target lesions unless there has been demonstrated progression in those lesions.

  3. Patients must understand and voluntarily sign an informed consent document before any study-related assessments/procedures being conducted.
  4. Patients must be able and willing to comply with the study visit schedule and protocol requirements.
  5. Patients must have a clinical performance of Eastern Cooperative Oncology Group (ECOG) 0 or 1.
  6. Patients are considered medically fit enough to undergo all study procedures and interventions and adequate hematological, renal and hepatic functions defined by:

    1. ≥9.0 g/dL.
    2. An ≥1000/mm3 without the support of filgrastim.
    3. ≥ 100 x10⁹ /mm3.
    4. PT and ≤1.5 x (ULN, unless receiving therapeutic anticoagulation). Subjects receiving therapeutic anticoagulation (such as low-molecularweight heparin or warfarin) should be on a stable dose.
    5. or ALT ≤3 x ULN. Patients with liver metastases must have AST and ALT ≤5.0 x ULN.
    6. Total \<2 mg/dL. Patients with Gilbert's Syndrome must have a total bilirubin ≤3.0 mg/dL.
    7. Serum creatinine \<1.5 mg/dL or measured ≥50 ml/min calculated using the Cockcroft-Gault estimation: (140 - age) × (weight in kg) × (0.85 if female)/72 × (serum creatinine in mg/dL).
  7. Patients must be seronegative for HIV antibody.
  8. Patients must be seronegative for active hepatitis B (defined as having a negative hepatitis B surface antigen [HBsAg] test), and seronegative for hepatitis C antibody. Patients with a history of hepatitis B virus (HBV) infection and having a negative HBsAg test and a positive antibody to hepatitis B surface antigen (HBsAg) are eligible. Patients with the hepatitis C antibody test positive are eligible only if tested for the presence of antigen by RT-PCR and be HCV RNA negative.
  9. Life expectancy ≥3 months.
  10. Patients who are of childbearing potential (postmenarcheal who has not reached a postmenopausal state and has not undergone surgical sterilization) or have partners of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 6 months after the last dose of IL-2.
  11. Female participants: a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Women of non-childbearing potential (WONCBP).
    2. Women of childbearing potential (WOCBP), who:

    i. Agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \<1% per year from screening until 6 months after the infusion of the NEXTGEN-TIL product. Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal occlusion, male sterilization, and copper intrauterine devices.

    ii. Have a negative pregnancy test (blood) within one week before the first study treatment administration (applicable to premenopausal women and women ≤2 years after the start of menopause (menopause is defined as amenorrhea for \<2 years).

  12. Male Participants: during the treatment period and for at least 2 months after the last dose of study treatment, agreement to:

    1. Remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom or a contraceptive method that result in a failure rate of \<1% per year, with partners who are WOCBP.
    2. Refrain from donating sperm during the study.
    3. Inform if his partner gets pregnant during this time.
  13. Any toxicity related to prior systemic therapy must have recovered to grade 1 or less according to v5.0 at least 4 weeks before treatment enrollment, except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy, and Grade ≤2 peripheral neuropathy.

    Note: Other Grade 2 AEs that are deemed clinically insignificant by treating physician and in consultation with Medical Monitor are permitted.

  14. Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.

Exclusion Criteria (any phase):

  1. Patients with symptomatic and/or untreated . Note: Patients with definitively-treated brain metastases will be considered for enrollment after discussion with Medical Monitor; if, prior to the start of NMA-LD the patient is clinically stable for ≥3 months, there are no new brain lesions via magnetic resonance imaging (MRI) post-treatment, and the patient does not require treatment >10 mg prednisone or equivalent per day.
  2. Patients with .
  3. Patients with an active concurrent or history within the past 3 years of invasive , except for non-melanoma skin cancer, cervical and bladder carcinoma in situ, good prognosis ductal carcinoma in situ of the breast, or prostate carcinoma that is in remission under androgen deprivation therapy for > 2 years. Other exceptions may apply and require discussion between the Investigator and the Medical Monitor.
  4. Patients with an active systemic infection requiring anti-infective treatment within 14 days before preparative lymphodepleting therapy.
  5. Patients with active hepatitis B or hepatitis C.
  6. Patients with active disease requiring treatments.
  7. Patients with a history of organ or bone marrow transplantation.
  8. Patients with any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).
  9. Patients requiring regular treatment with steroids at a dose higher than prednisone 10 mg/day (or equivalent).

    Note: use of inhaled, topical steroids and use of systemic physiologic corticosteroid replacement therapy are permitted.

  10. Patients with current or history within the last 6 months, as determined by the Investigator, of , progressive, and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastroenterological or neurological disease.
  11. Patients with a history of coronary revascularization or ischemic symptoms.
  12. History of idiopathic pulmonary fibrosis or evidence of active pneumonitis (any origin)
  13. Patients with allergies to any of the compounds included in any of the treatment products.
  14. Patients with for cyclophosphamide, fludarabine and IL-2 at per protocol doses.
  15. Patients who have received any approved anti-cancer cytotoxic, anti-angiogenic and ICB therapy including radiotherapy within 4 weeks before preparative lymphodepleting therapy. Exception: palliative radiotherapy for bone metastasis >2 weeks before preparative lymphodepleting therapy, denosumab, bisphosphonates, androgen deprivation therapy for prostate cancer and hormonal therapy for breast cancer.
  16. Patients who have received any non-cytotoxic drug and molecular targeted therapy within 4 weeks before preparative lymphodepleting therapy (or within five half-lives of the product, whichever is shorter).
  17. Patients who have received any investigational agent within 4 weeks before preparative lymphodepleting therapy (or within five half-lives of the investigational product, whichever is shorter).
  18. Patients who have received a live, attenuated vaccination within the 4 weeks before lymphodepleting therapy.
  19. Patients who have undergone major surgery in the previous 3 weeks before lymphodepleting therapy.
  20. Patients who have previously received any investigational cell or gene therapies.
  21. Women of childbearing potential who are pregnant or breastfeeding.
  22. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    NEXTGEN-TIL

    Subjects will receive Tumor-infiltrating Lymphocyte (NEXTGEN-TIL) therapy preceded by a preparative non-myeloablative lymphodepleting (NMA-LD) regimen and followed by IL-2 infusion. Patients will be followed weekly until week 4 after NEXTGEN-TIL infusion, and subsequently at weeks 6, 9, 12, 18, 24, 30, 36, and at 1 year, 1.5 years, and 2 years. After the 2-year follow-up period, long-term clinical follow-up for disease progression and survival will continue for up to 60 months after the last IL-2 dose, unless the patient withdraws consent for further follow-up.

    Biological: NEXTGEN-TIL · Drug: Non-myeloablative Lymphodepletion (NMA-LD) Regimen · Drug: Interleukin-2

Interventions

  • BiologicalNEXTGEN-TIL

    NEXTGEN-TIL product is a cellular investigational product comprising a live cell suspension of autologous tumor-infiltrating lymphocytes derived from the patient's own tumor. Each dose contains at least 5 × 10⁸ and a maximum of 7.5 × 10¹¹ total viable lymphocytes. The product will be administered intravenously on Day 0.

    Also known as: Tumor-infiltrating Lymphocyte Adoptive Cell Therapy

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive cyclophosphamide 60 mg/kg IV once daily on Days -7 and -6, followed by fludarabine 25 mg/m² IV once daily on Days -5 to -1.

    Also known as: Cyclophosphamide, Fludarabine

  • Patients will receive IL-2 at a dose of 600,000 IU/kg IV, starting 3 to 24 hours after completion of NEXTGEN-TIL infusion, for up to six doses administered every 8 to 24 hours as tolerated, on Days 0 to 2.

    Also known as: IL-2, Aldesleukin

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AE)

    Nature and frequency of AE, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From pre-treatment consent to lymphodepletion, only AEs related to protocol-mandated procedures are recorded. From lymphodepletion to 30 days after the last IL-2 dose or next anticancer therapy, whichever comes first, all AEs are recorded.

  2. Incidence of Serious Adverse Events (SAE)

    Nature and frequency of SAE, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: From baseline through 6 months from the last dose of IL-2 or until the first dose of the next anticancer therapy, whichever occurs first

  3. Treatment-limiting Toxicity (TLT)

    Toxicities related to treatment administration that, if recurrent at high enough frequency (≥2 patients treated), should trigger review by the Independent Data Safety Monitoring Board (IDSMB), which could lead to recommendations for treatment modifications for subsequent patients.

    Time frame: Within the 30-day TLT assessment period starting with the first dose of lymphodepleting chemotherapy (Day -7).

  4. Incidence of alterations in clinical laboratory test results

    Nature and frequency of abnormalities found in clinical laboratory test results

    Time frame: From baseline through study completion, an average of 2 years

  5. Incidence of alterations in electrocardiogram assessment

    Nature and frequency of abnormalities found in electrocardiogram

    Time frame: From baseline through study completion, an average of 2 years

  6. Incidence of alterations in vital signs measurements

    Nature and frequency of abnormalities found in vital signs.

    Time frame: From baseline through study completion, an average of 2 years

  7. Incidence of physical examination findings

    Nature and frequency of abnormalities found in the physical examination.

    Time frame: From baseline through study completion, an average of 2 years

  8. Assessment of performance status

    Patient performance status assessed as per Eastern Cooperative Oncology Group (ECOG) score, where grade 0 is for fully active and capable patient and grade 5 is death.

    Time frame: From baseline through study completion, an average of 2 years

Secondary outcomes

  1. Neoantigen-selected TIL analysis

    Rate of successful neoantigen-selected TIL (NEXTGEN-TIL) generation from biopsied patients and frequency of neoantigen-specific TILs in all TILs produced from biopsied patients included in this trial.

    Time frame: At baseline

  2. Overall Response Rate (ORR)

    ORR per RECIST v1.1 as assessed by investigator, defined as proportion of patients who have a partial or complete response to therapy.

    Time frame: From baseline through disease progression, assessed up to 36 months after last dose of IL-2

  3. Duration of Response (DOR)

    DOR per RECIST v1.1 as assessed by investigator, defined as the time elapsed between the initial response to therapy and subsequent disease progression or relapse.

    Time frame: From baseline through disease progression, assessed up to 36 months after last dose of IL-2

  4. Progression-Free Survival (PFS)

    PFS per RECIST v1.1 as assessed by investigator, defined as the time from the date of treatment administration to the date of first documentation of disease progression or death due to any cause, whichever occurs first. For a patient who has not progressed and is last known to be alive, PFS will be censored at the last response assessment that is stable disease (SD) or better.

    Time frame: From baseline through disease progression, assessed up to 36 months after last dose of IL-2

07

Study locations

1 of 1 sites recruiting
  • Vall d'Hebron Institute of Oncology
    Barcelona, Spain
    Recruiting
    • Elena Garralda, MD · Contactegarralda@vhio.net · 0034 93 489 30 00
    • Elena Garralda, MD · Principal investigator
    • Vladimir Galvão de Aguiar, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Jan 2027, 62 months after the start.

Of 71 phase 1 interventional studies under Carcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Dec 2, 2021
StartActual
Oct 28, 2021
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameIncidence of Adverse Events (AE)From baseline through 6 months from the last dose of IL-2 or until the first dose of the next anticancer therapy, whichever occurs first → From pre-treatment consent to lymphodepletion, only AEs related to protocol-mandated procedures are recorded. From lymphodepletion to 30 days after the last IL-2 dose or next anticancer therapy, whichever comes first, all AEs are recorded.
  • Time frameTreatment-limiting Toxicity (TLT)From the first dose of study treatment (Day -5) to 30 days after → Within the 30-day TLT assessment period starting with the first dose of lymphodepleting chemotherapy (Day -7).
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameIncidence of Adverse Events (AE)From baseline through 6 months from the last dose of IL-2 or until the first dose of the next anticancer therapy, whichever occurs first → From pre-treatment consent to lymphodepletion, only AEs related to protocol-mandated procedures are recorded. From lymphodepletion to 30 days after the last IL-2 dose or next anticancer therapy, whichever comes first, all AEs are recorded.
    • Time frameTreatment-limiting Toxicity (TLT)From the first dose of study treatment (Day -5) to 30 days after → Within the 30-day TLT assessment period starting with the first dose of lymphodepleting chemotherapy (Day -7).
    + 3 other changes: verification date, oversight details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05141474
Lead sponsor
Vall d'Hebron Institute of Oncology
Collaborators
Banc de Sang i Teixits
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Oct 28, 2021
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Elena Garralda
Contact
egarralda@vhio.net
0034 93 489 30 00
Susana Muñoz
Contact
smunoz@vhio.net
Elena Garralda
principal investigator · Vall d'Hebron Institute of Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin-2

Start the discussion